Butantan's dengue vaccine has an overall efficacy of 79%, study shows.
The study's effectiveness in combating the infection showed positive results in people with and without prior exposure to the disease.
247 - Results from a study published this Wednesday (31) in the scientific journal "New England Journal of Medicine (NEJM)" indicated that the dengue vaccine being developed by the Butantan Institute (SP) has an overall efficacy of 79,6% in preventing the disease.
According to the research, which provided information from a three-year follow-up with more than 16 people in Brazil, the effectiveness in combating the infection had positive results in people with and without prior exposure to dengue: 89,2% in individuals who were diagnosed with the disease before the study, and 73,6% in those who had never been in contact with the virus.
The efficacy rate (79,6%) is similar to that found in clinical trials of Qdenga (80,2%), a dengue vaccine from the Japanese laboratory Takeda that will be offered in the Unified Health System (SUS) starting this year, in two doses. The Brazilian vaccine, promised for 2025, will be administered in a single dose.